TNFSF11 and Miyoshi myopathy: For example, a recent study introduced dual targeting of PD-1 and receptor activator of nuclear factor kappa-B ligand (RANKL) to simultaneously block immune checkpoint-mediated immune suppression and reduce osteoclast formation that, thereby, may increase immunotherapeutic anti-MM activity [50].